Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
13,966
result(s) for
"Harris, Sam A"
Sort by:
Sebze : vegetarian recipes from my Turkish kitchen
Inspired by thousands of years of rich and diverse culinary heritage, Sebze is a recipe collection built with convenience and flavour in mind, championing popular Turkish classics, along with lesser-known regional specialties, such as Gözleme (Stuffed Flatbreads), Çılbır (Turkish Style Poached Eggs with Garlicky Yoghurt), Beetroot with Walnuts and Pomegranate Molasses Easy, Herby Pan Börek, Otlu tava böreği, Nohut Dürümü (Gaziantep's Spiced Chickpea Wrap) and more. You will be glad to know there are scrumptious sweet treats in Sebze too, from the Turkish classic milk-based Fırın Sütlaç to the luscious Pumpkin and Walnut Baklava - Özlem Warren's take on the much loved classic. A passionate and skilled advocate for her national cuisine, Özlem will show you how to make meals that you want to - and can - cook, making Sebze the perfect introduction to Turkish food for the home cook.
BOOK
The British cookbook
Discover over 550 much-loved recipes celebrating the rich traditions of regional and seasonal British cooking.
Book
DEAL JUSTLY, IRAN
The verdict in the show trial of 13 Iranian Jews is expected today - the Jewish Sabbath - in Shiraz, Iran. Iranian judiciary officials announced on June 25 that the 13, who are accused of spying for Israel, could face the death penalty if convicted. Given the Islamic regime's record - executing 17 Jews since the revolution in 1979 - the prospects for these 13, who were imprisoned more than a year ago, appear grim. At first, Iranian authorities accused the 13 of holding religious classes and printing religious material. Several months later, after their arrest became international news, the Iranian Ministry of Information accused them of spying on behalf of Israel and the United States. Then, stunned by diplomatic protests from dozens of countries, Iranian officials accused them of spying on behalf of Israel, Iraq and Turkey - and plotting to poison the water supply of Shiraz, an insidious claim eerily reminiscent of medieval anti- Semitic canards.
Newspaper Article
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based or fluoropyrimidine chemotherapy. Patients who were ctDNA-negative were not treated. The primary efficacy end point was recurrence-free survival at 2 years. A key secondary end point was adjuvant chemotherapy use.
Of the 455 patients who underwent randomization, 302 were assigned to ctDNA-guided management and 153 to standard management. The median follow-up was 37 months. A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65). In the evaluation of 2-year recurrence-free survival, ctDNA-guided management was noninferior to standard management (93.5% and 92.4%, respectively; absolute difference, 1.1 percentage points; 95% CI, -4.1 to 6.2 [noninferiority margin, -8.5 percentage points]). Three-year recurrence-free survival was 86.4% among ctDNA-positive patients who received adjuvant chemotherapy and 92.5% among ctDNA-negative patients who did not.
A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.).
Journal Article
Neural correlates of maintaining one’s political beliefs in the face of counterevidence
People often discount evidence that contradicts their firmly held beliefs. However, little is known about the neural mechanisms that govern this behavior. We used neuroimaging to investigate the neural systems involved in maintaining belief in the face of counterevidence, presenting 40 liberals with arguments that contradicted their strongly held political and non-political views. Challenges to political beliefs produced increased activity in the default mode network—a set of interconnected structures associated with self-representation and disengagement from the external world. Trials with greater belief resistance showed increased response in the dorsomedial prefrontal cortex and decreased activity in the orbitofrontal cortex. We also found that participants who changed their minds more showed less BOLD signal in the insula and the amygdala when evaluating counterevidence. These results highlight the role of emotion in belief-change resistance and offer insight into the neural systems involved in belief maintenance, motivated reasoning, and related phenomena.
Journal Article